JP2015500885A - 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 - Google Patents

癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 Download PDF

Info

Publication number
JP2015500885A
JP2015500885A JP2014548917A JP2014548917A JP2015500885A JP 2015500885 A JP2015500885 A JP 2015500885A JP 2014548917 A JP2014548917 A JP 2014548917A JP 2014548917 A JP2014548917 A JP 2014548917A JP 2015500885 A JP2015500885 A JP 2015500885A
Authority
JP
Japan
Prior art keywords
formula
alkyl
cancer
administered
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500885A5 (https=
Inventor
ハート，チャールズ
モン，ファンイン
サン，ジェシカ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2015500885A publication Critical patent/JP2015500885A/ja
Publication of JP2015500885A5 publication Critical patent/JP2015500885A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014548917A 2011-12-22 2012-12-20 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 Pending JP2015500885A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579605P 2011-12-22 2011-12-22
US61/579,605 2011-12-22
US201261617576P 2012-03-29 2012-03-29
US61/617,576 2012-03-29
PCT/US2012/071074 WO2013096687A1 (en) 2011-12-22 2012-12-20 Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017182053A Division JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Publications (2)

Publication Number Publication Date
JP2015500885A true JP2015500885A (ja) 2015-01-08
JP2015500885A5 JP2015500885A5 (https=) 2016-02-18

Family

ID=48669508

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548917A Pending JP2015500885A (ja) 2011-12-22 2012-12-20 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
JP2017182053A Withdrawn JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017182053A Withdrawn JP2017218459A (ja) 2011-12-22 2017-09-22 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与

Country Status (4)

Country Link
US (1) US9254299B2 (https=)
EP (1) EP2793882A4 (https=)
JP (2) JP2015500885A (https=)
WO (1) WO2013096687A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528217A (ja) 2013-07-26 2016-09-15 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
EP3313819A1 (en) * 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer
CA3065803A1 (en) * 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
MX2021013905A (es) * 2019-05-14 2022-05-18 Sierra Oncology Inc Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
CN117651548B (zh) 2021-08-27 2026-03-03 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20250160163A (ko) 2023-02-27 2025-11-11 아센타위츠 파마슈티컬즈 리미티드 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502743A (ja) * 2005-06-29 2009-01-29 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
JP2010514787A (ja) * 2006-12-26 2010-05-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306727A (en) 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US7914994B2 (en) 1998-12-24 2011-03-29 Cepheid Method for separating an analyte from a sample
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
DE10237931A1 (de) 2002-08-14 2004-02-26 Endress + Hauser Gmbh + Co. Kg Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
AU2004285831B2 (en) 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
US7432106B2 (en) 2004-03-24 2008-10-07 Applied Biosystems Inc. Liquid processing device including gas trap, and system and method
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1743038A4 (en) 2004-05-04 2007-11-21 Bayer Healthcare MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
CA2624707A1 (en) 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
WO2008033041A1 (en) 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
US7807454B2 (en) 2006-10-18 2010-10-05 The Regents Of The University Of California Microfluidic magnetophoretic device and methods for using the same
US8216607B2 (en) 2008-03-17 2012-07-10 Roger Williams Hospital Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
TWI466886B (zh) 2008-06-11 2015-01-01 Genentech Inc 二氮雜咔唑及使用方法
EP2350664B1 (en) 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
US8281672B2 (en) 2009-03-20 2012-10-09 Pbs Biotech, Inc. Automatable aseptic sample withdrawal system
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
US20110135739A1 (en) 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor
US20130296273A1 (en) 2010-06-28 2013-11-07 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
ES2877629T3 (es) 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
EP2593796A4 (en) 2010-07-16 2016-07-27 Auckland Uniservices Ltd BACTERIAL NITROREDUCTASE ENZYMES AND METHOD THEREFOR
WO2012135757A2 (en) 2011-04-01 2012-10-04 Threshold Pharmaceuticals, Inc. Methods for treating cancer
RU2013147744A (ru) 2011-04-15 2015-05-20 Тресхолд Фармасьютикалз, Инк. Дозированная лекарственная форма для перорального применения
JP5805989B2 (ja) 2011-04-26 2015-11-10 大塚電子株式会社 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
JP2015511226A (ja) 2012-01-31 2015-04-16 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502743A (ja) * 2005-06-29 2009-01-29 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
JP2010514787A (ja) * 2006-12-26 2010-05-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HU, J. ET AL.: ""Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug"", BLOOD, vol. 116, no. 9, JPN6016036808, 2 September 2010 (2010-09-02), pages 1524 - 1527, ISSN: 0003406235 *
MA, C.X. ET AL.: ""Death by releaseing the breaks: CHK1 inhibitors as cancer therapeutics"", TRENDS MOL. MED., vol. 17, no. 2, JPN6016036806, February 2011 (2011-02-01), pages 88 - 96, ISSN: 0003406234 *
ZABLUDOFF, S.D. ET AL.: ""AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targ", MOL. CANCER THER., vol. 7, no. 9, JPN6016036804, September 2008 (2008-09-01), pages 2955 - 2966, ISSN: 0003406233 *

Also Published As

Publication number Publication date
EP2793882A4 (en) 2015-04-29
US9254299B2 (en) 2016-02-09
JP2017218459A (ja) 2017-12-14
EP2793882A1 (en) 2014-10-29
WO2013096687A1 (en) 2013-06-27
US20150005263A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
JP2017218459A (ja) 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
US20250295869A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
KR102908092B1 (ko) Cxcr4 억제제의 조성물 및 제조 방법 및 용도
JP7194022B2 (ja) Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
CN103458896B (zh) 用于治疗癌症的方法
US20150005262A1 (en) Hypoxia activated prodrugs and mtor inhibitors for treating cancer
JP2013533257A (ja) 血液癌の治療法
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
TWI649082B (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
HK1254083B (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2025078334A1 (en) Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia
AU2011279391A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170523